At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Aspirin in Adults With Nonalcoholic Fatty Liver Disease
In Brief
A Phase 2 clinical trial evaluating Aspirin 81 mg and Placebo oral tablet for Nonalcoholic Fatty Liver and Nonalcoholic Steatohepatitis. Completed, enrolled 80 participants across 1 site.
Detailed Summary
Nonalcoholic fatty liver disease (NAFLD), defined by fatty infiltration of the liver in the absence of excess alcohol consumption, affects an estimated 30% of adults in the United States. A proportion of people with NAFLD will develop progressive, inflammatory nonalcoholic steatohepatitis (NASH), which can progress to liver cirrhosis and liver failure. NAFLD is expected to be the most common indication for liver transplantation by the year 2020. We hypothesize that among adults with NAFLD, aspirin will reduce intrahepatic lipid content, as quantified by 1H magnetic resonance spectroscopy (1H-MRS).
Study Details
Timeline
Interventions
Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.
Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.